Guidelines for the safe use of radioactive materials during localization and resection of the sentinel lymph node

Annals of Surgical Oncology

Volumn 6, Issue 1, 1999, Pages 75-82

  Miner, Thomas J ^a   Shriver, Craig D ^a   Flicek, Paul R ^a   Miner, Frederick C ^b   Jaques, David P ^a   Maniscalco Theberge, Mary E ^a   Krag, David N ^c  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b Ryley Carlock Applewhite A   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; Lymph node; Melanoma; Radiation; Technetium

Indexed keywords

RADIOACTIVE MATERIAL; TECHNETIUM;

ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CANCER SURVIVAL; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; LYMPHATIC DRAINAGE; LYMPHOSCINTIGRAPHY; MELANOMA; PRACTICE GUIDELINE; RADIATION EXPOSURE; TUMOR LOCALIZATION;

BIOPSY; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MELANOMA; PRACTICE GUIDELINES; RADIATION DOSAGE; RADIATION PROTECTION; RADIOPHARMACEUTICALS; SAFETY; SKIN NEOPLASMS; TECHNETIUM TC 99M SULFUR COLLOID;

EID: 0033059529     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10434-999-0075-7     Document Type: Article

References (56)

1. Balch CM. The role of elective lymph node dissection in melanoma: rationale, results and controversies. J Clin Oncol 1988;6: 163,392.
2. Day CL, Lew RA. Malignant melanoma prognostic factors: elective lymph node dissection. J Dermatol Surg Oncol 1985;11: 233-9.
3. Veronesi U, Adarnus J, Bandera DC. Delayed regional lymph node dissection in Stage I melanoma of the skin of the lower extremities. Cancer 1982;42:2420-30.
4. Balch CM, Soong SJ, Milton GW. A comparison of prognostic factors and surgical results in 1,786 patients with localized (Stage 1) melanoma treated in Alabama, USA and New South Wales, Australia. Ann Surg 1982;196:677-84.
5. Balch CM. Surgical management of regional lymph nodes in cutaneous melanoma. J Am Acad Dermatol 1980;3:511-24.
6. Veronesi U, Adamus J, Bandiera DC, et al. Inefficacy of immediate node dissection in stage I melanoma of the limbs. W Engl J Med 1977;297:627-30.
7. Sugarbaker EV, McBride CM. Melanoma of the trunk: the results of surgical excision and anatomic guidelines for predicting nodal metastasis. Surgery 1976;80:22-30.
8. Sim FH, Taylor VYT, Ivins JC, Soule EH. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malianant melanoma: preliminary results. Cancer 1978;41:948-56.
9. White RE, Vezeridis MP, Konstadoulakis M, Cole BF, Wanebo HT, Bland KI. Therapeutic options and results for the management of minimally invasive carcinoma of the breast: influence of axillary dissection for treatment of Tla and Tlb lesions. J Am Coll Surg 1996;183:575-88.
10. Silverstein MJ, Gierson ED, Waisman JR, Sanofsky GM, Colburn WJ, Ganagami P. Axillary lymph node dissection for Tla breast carcinoma. Cancer 1994;73:664-7.
11. Halverson KJ, Taylor ME, Perez CA, et al. Management of the axilla in patients with breast cancers one centimeter and smaller. Am J Clin Oncol 1994;17:461-6.
12. Chadha M, Chabon AB, Friedmann P, Vikram B. Predictors of axillary lymph node metastases in patients with Tl breast cancer: a multivariate analysis. Cancer 1994;73:350-3.
13. Cady B. The need to reexamine axillary lymph node dissection in invasive breast cancer. Cancer 1994;73:505-8.
14. Morrow M. Axillary dissection in breast cancer: what role in managing BCa? Contemp Oncol 1994;4:16-27.
15. Walls J, Boggis CRM, Wilson M, Asbury DL, Roberts JV, Brindred NJ, Mansel RF. Treatment of the axilla in patients with screen-detected breast cancer. Br J Surg 1993;80:436-8.
16. Deckers PJ. Axillary dissection in breast cancer: when, why, how much, and or how long? Another operation soon to be extinct? J Surg Oncol 1991;48:217-9.
17. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-9.
18. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994;220:391-401.
19. Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1996;222:394-401.
20. Alex JC, Weaver DL, Fairbank JT, Krag DN. Gamma-probeguided lymph node localization in malignant melanoma. Surg Oncol 1993;2:303-8.
21. VanDerVeen H, Hoekstra OS, Paul MA, Cuestra MA, Meyer S. Gamma probe-guided sentinel node biopsy to select patients with melanoma for lymphadenectomy. Br J Surg 1994;81:1769-70.
22. Albertini JJ, Cruse CW, Rappaport D, et al. Intraoperative radiolymphoscintigraphy improves sentinel lymph node identification for patients with melanoma. Ann Surg 1996;223:217-24.
23. Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993;2:335-40.
24. Albertini JJ, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996;276:1818-22.
25. Ross ML, Reinigen DS, Balch CM. Selective lymphadenectomy: emerging role for lymphatic mapping and sentinel node biopsy in the management of early stage melanoma. Semin Surg Oncol 1993;9:219-23.
26. Krag DN, Meijer SJ, Weaver DL, et al. Minimal-access surgery for staging of malignant melanoma. Arch Surg 1995;130:654-60.
27. Reinigen D, Balch CM, Kirkwood J, Ross M. Recent advances in the care of the patient with malignant melanoma. Ann Surg 1997; 225:1-14.
28. Alazraki N. Lymphoscintigraphy and the intraoperalive gamma probe. J Nucl Med 1995;36:1780-3.
29. Hirsch J, Tisnado J, Shoa-Ru C, Beachley M. Use of isosulfan blue for identification of lymphatic vessels: experimenlal and clinical evaluation. AJR 1982;139:1061-4.
30. Alex JC, Krag DN. Gamma-probe guided localization of lymph nodes. Surg Oncol 1993;2:137-43.
31. Uren RF, Howman-Giles RB, Thompson JF, Malouf D, Ramsey-Stewart G, Niesche FW, Renwick SB. Mammary lymphoscintigraphy in breast cancer. J Nucl Med 1995;36:1775-80.
32. Boak JL, Agwunobi TC. A study of technetium-labeled sulphide colloid uptake by regional lymph draining of tumor-bearing area. Br J Surg 1979;65:374-8.
33. Meyer CM, Lecklitner NM, Logic JR, Balch CE, Bessey PQ, Tauxe WN. Technetium 99m sulfur colloid cutaneous lymphoscintigraphy in the management of truncal melanoma. Radiology 1979; 131:205-9.
34. Kaplan WD, Davis MA, Rose CM. A comparison of two technetium 99m-Iabeled radiopharmaceuticals for lymphoscintigraphy: concise communication. J Nucl Med 1979;20:933-7.
35. Vendrell-Tome E, Seroain-Quinquer J, Domenech-Tome FM. Study of normal lymphatic drainage using radioactive isotopes. J Nucl Med 1972;13:801-5.
36. Ege G, Warbick A. Lymphoscintigraphy: a comparison of 99Tc antimony sulphide colloid and 99Tc-stannous phylate. Br J Radiol 1979;52:124-9.
37. Shleien B, ed. The health physics and radiological health handbook. Silver Spring, MD: Scinta, 1992:65-102.
38. Title 49. Code of Federal Regulations. Section 173.403. Washington, DC: Government Printing Office, 1995.
39. Title 10. Code of Federal Regulations. Section 20.1301. Washington, DC: Government Printing Office, 1995.
40. Title 10. Code of Federal Regulations. Section 20.1302. Washington, DC: Government Printing Office, 1995.
41. Title 10. Code of Federal Regulations. Section 35.11. Washington, DC: Government Printing Office, 1994.
42. Title 10. Code of Federal Regulations. Section 20.1001. Washington, DC: Government Printing Office, 1991.
43. Title 10. Code of Federal Regulations. Section 20.1002. Washington, DC: Government Printing Office, 1995.
44. Title 10. Code of Federal Regulations. Section 35.20. Washington, DC: Government Printing Office, 1986.
45. US Nuclear Regulatory Commission Regulatory Guide, 8.29 (Rev. 1). Washington, DC: US Nuclear Regulatory Commission, February, 1996.
46. Title 10. Code of Federal Regulations. Section 35.990. Washington, DC: Government Printing Office, 1992.
47. Title 10. Code of Federal Regulations. Section 35.991. Washington, DC: Government Printing Office, 1994.
48. Title 10. Code of Federal Regulations. Section 20.2001. Washington, DC: Government Printing Office, 1991.
49. Title 10. Code of Federal Regulations. Section 20.303. Washington, DC: Government Printing Office, 1982.
50. US Nuclear Regulatory Commission. Applicability of 10 CFR 20.303 to disposable diapers soiled with contaminated excreta. Washington, DC: US Nuclear Regulatory Commission, 1979. (HP-POS - 034).
51. Title 10. Code of Federal Regulations. Section 19, subpart J. Washington, DC: Government Printing Office, 1995.
52. Title 10. Code of Federal Regulations. Section 20.1201. Washington, DC: Government Printing Office, 1995.
53. Title 10. Code of Federal Regulations. Section 20.1502. Washington, DC: Government Printing Office, 1995.
54. Title 10. Code of Federal Regulations. Section 35.200. Washington, DC: Government Printing Office, 1994.
55. Title 10. Code of Federal Regulations. Section 35.70. Washington, DC: Government Printing Office, 1997.
56. US Nuclear Regulatory Commission Regulatory Guide, 10.8 (Appendix N-1). Washington, DC; US Nuclear Regulatory Commission, December, 1994.